Industrial Technology Research Institute

Tsan-Lin Hu

Chih-Peng Liu

Yuan-Jang Tsai

Chrong-Shiong Hwang

Chen-Yi Su

Chia-Mu Tu

On Lee

Kuo-Kuei Huang

Yen-Chun Chen

Meng-Nan Lin

Maggie Lu

Jenn-Tsang Hwang

Maggie J M Lu

Yu-Chin Lin

Min-Ying Lin

Felice Cheng

Shuen-Hsiang Chou

Chia-Ching Chen

Yen-Fang Wen

Chiu-Lien Hung

Chih-Wei Fu

Shao-Chan Yin

Po-Hung Lai

Yu-Wen Lo

Chien-Chin Huang

Chien-Lin Pan

Wen-Chia Huang

Hao-Hsuan Liu

Wan-Ru Chen

Yen-Jen Wang

Shing-Mein Wu

Chiu Hsing Lin

Shing Mein Wu

Chia-Wen Huang

An androgen receptor (AR) binding molecule has the structure of Formula (I) shown in the following: wherein E is CH, G is CH, is OH, NH, OTf or C≡C, X is CFor trifluoromethylphenyl,is a single bond, and Y and Z are CH; or is absent, X is CF,is a double bond, and Y and Z are CH.

Androgen receptor binding molecule and use thereof

A composition for improving the solubility of poorly soluble substances is provided. The composition includes about 40-99.5% by weight of cyclodextrin and/or derivatives thereof; about 0.05-10% by weight of at least one water-soluble polymer; and about 0.05-60% by weight of at least one water-soluble stabilizer.

Composition for improving the solubility of poorly soluble substances, use thereof and complex formulation containing thereof

The disclosure provides a pharmaceutical composition. The pharmaceutical composition includes a chitosan with palmitoyl groups and an active agent. According to another embodiment, the pharmaceutical composition can further include a gelling accelerating agent. According to an embodiment of the disclosure, the active agent of the disclosure can be administered in the form of a nano-drug, liposome, micelle, or microparticle.

Pharmaceutical composition

The disclosure is directed to a monohydrate crystalline form of 3-(5-(4-(3-fluoropropyl)piperazin-1-yl)benzimidazol-2-yl)-1-azaazulen-2-one, possessing diffraction peaks of about 12.9&#xb0;, 15.9&#xb0;, 17.9&#xb0;, 21.2&#xb0;, 22.9&#xb0;, 23.5&#xb0; and 24.5&#xb0;. Its preparation method and pharmaceutical composition thereof are also provided.

Monohydrate crystalline form of 3-(5-(4-(3-fluoropropyl)-piperazin-1-yl)benzimidazol-2-yl)-1-azaazulen-2-one, preparation, and pharmaceutical composition thereof

An oligopeptide comprises formulae (I) or (II)  the oligopeptide derivative thereof, and a pharmaceutical composition comprising the same are provided.

NAP derivatives

The present invention provides a neurodegenerative, non-human transgenic mammal whose cells contain a TrkA-hFc transgene for encoding at least a TrkA fusion protein and the use thereof.

Neurodegenerative non-human transgenic mammal expressing TrkA fusion protein

Growing community of inventors

Jhubei, Taiwan

Tsan-Lin Hu